TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06480292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telerehabilitation exercise
Description: 5 min warmup will include ankle plantar and dorsiflexion ,trunk side flexion ,shoulder circles ,shoulder ROMS.it will be followed by 5 min aerobics that includes spot marching and side stepping. it will be followed by resistance exercise which will be divided into 3 groups. each group of exercise will be performed one day each. chair squats, arm pulls, seated triceps, biceps curls etc. are included in these resistance exercises. intensity of each exercise will be progressively increased.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine medical care
Description: The control group will be given routine medical care (including dietary modification, oral anti diabetics (metformin) and advised to do regular walk (20-30min/day).
Study: NCT05133323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG09222
Description: Lu AG09222 will be administered per schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG09222
Description: Lu AG09222 will be administered per schedule specified in the arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to Lu AG09222 will be administered per schedule specified in the arm.
Study: NCT05619666

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Acute rehabilitation program
Description: Patients included in the study started the rehabilitation program when they were hemodynamic stable, when it was determined that it was safe for patients. Until discharge from the hospital, a re-evaluation of neuromuscular and respiratory function was performed.
Study: NCT04797507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210 plus Anlotinib
Description: SHR-1210: a novel anti-PD-1 antibody Anlotinib: a multi-kinase inhibitor
Study: NCT05010213

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Educational intervention
Study: NCT05293522

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NTX-001
Description: 2 solutions plus a delivery device; one time use surgical product
Study: NCT05822739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBM-P002
Description: Genetic: single- dose intracranial injection of BBM-P002 Neurosurgical delivery of BBM-P002 to the brain
Study: NCT05369559

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Mini bolus 50
Description: receiving a mini-bolus A:50 ml of crystalloid solution, regularly infused over 30 seconds
Study: NCT05597995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Tetradecyl Sulfate
Description: subjects epidermoid cysts will be treated with 1.5% sodium tetradecyl sulfate foam
Study: NCT04797208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-Time CGM
Description: Participants will be wearing a real-time continuous glucose sensor which will enable their glucose levels to be remotely monitored. High and Low glucose alerts will also be available.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Capillary blood glucose testing with masked CGM
Description: Participants will have their glucose monitored in hospital in the conventional manner using the NovaStat® glucometer or similar CE-marked glucose meter) and insulin dose adjusted by the treating clinical team as per usual hospital guidelines. A masked subcutaneous CGM will be inserted for data collection only.
Study: NCT04995068

Intervention type: RADIATION
Intervention: Head CT to determine presence of traumatic intracranial lesion
Description: Head CT to determine presence of traumatic intracranial lesion
Study: NCT06418113

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated stereotactic radiotherapy
Description: conformal hypofractionated stereotactic radiotherapy to the FLAIR hyperintense signal, including the contrast-enhancing tumor on T1, with a total dose of 3990 cGy at the margin in 15 fractions of 266 cGy, one session per day, five days a week, and concurrent temozolomide (TMZ) at 75 mg/m2/day for 7 days/week during the irradiation period

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic biopsy
Description: Stereotactic biopsy
Study: NCT05369559

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: passive leg rising test
Description: Passive leg raising technique: Initially, the patient is placed semi-recumbent with the head of the bed at 45°. After recording baseline measurement, the head of the bed is lowered and the legs are elevated to 45° for 2 minutes
Study: NCT04860362

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEERS
Description: Structured social skills curriculum including didactics, behavioral rehearsal, parent coaching, and parent coaching support.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PEERS
Description: Structured social skills curriculum including didactics, behavioral rehearsal, parent coaching, and parent coaching support.
Study: NCT05331690

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac Ophthalmic
Description: Topical nepafenac (Nevanac) 3 mg/ml starter the day before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac Ophthalmic
Description: Topical nepafenac (Nevanac) 3 mg/ml started the day after surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac Ophthalmic
Description: Topical nepafenac (Nevanac) 3 mg/ml started the day after surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Ophthalmic
Description: Topical dexamethasone 1 mg/ml (Spersadex) started the day after surgery
Study: NCT05518305

Intervention type: DIAGNOSTIC_TEST
Intervention: Medical Imaging
Description: magnetic resonance imaging
Study: NCT00956176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cidofovir
Description: Single dose of 5 mg/kg administered in 100 ml of normal saline solution through a foley catheter to bladder. The catheter will be clamped for 2 hours to keep the drug in bladder.
Study: NCT04995029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transmucosal Buprenorphine
Description: Transmucosal (TM) buprenorphine as selected by the Investigator per local prescribing guidelines, administered either under the tongue (sublingual) or between the gum and cheek (buccal)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transmucosal Buprenorphine
Description: Transmucosal (TM) buprenorphine as selected by the Investigator per local prescribing guidelines, administered either under the tongue (sublingual) or between the gum and cheek (buccal)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release Buprenorphine
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release Buprenorphine
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release Buprenorphine
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release Buprenorphine
Description: Administered by subcutaneous injection
Study: NCT06418113

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: resection
Description: supramarginal resection guided by 5-ALA under intraoperative neurophysiological monitoring

Intervention type: PROCEDURE
Group type: OTHER
Intervention: resection
Description: supramarginal resection guided by 5-ALA under intraoperative neurophysiological monitoring

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: 4 weeks post-surgery, temozolomide (TMZ) will be administered for 6 months
Study: NCT05067153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fragmin 5000 UNT in 0.2 ML Prefilled Syringe
Description: 30 days postoperative prophylactic treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fragmin 5000 UNT in 0.2 ML Prefilled Syringe
Description: 30 days postoperative prophylactic treatment.
Study: NCT06418113

Intervention type: RADIATION
Group type: OTHER
Intervention: radiotherapy Stupp protocol
Description: radiotherapy + TMZ concurrently after 4 weeks of resection surgery, as per usual protocol: Three-dimensional radiotherapy planning to deliver a total dose of 60 Gy, with a fractionation of 2 Gy/day, 5 days/week, encompassing a 1-2 cm margin around the contrast-enhancing region defined on T1 imaging or the entire abnormal volume defined on T2 or FLAIR imaging (Li et al., 2016) + TMZ at 75 mg/m2/day for 7 days/week, for 6 weeks during radiotherapy.

Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy Stupp Protocol
Description: temozolomide (TMZ) will be administered for 6 months according to the Stupp protocol.
Study: NCT05136053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG22515
Description: sterile solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG22515
Description: sterile solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG22515
Description: sterile solution for infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sterile solution for infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sterile solution for infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sterile solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune System Activator
Description: sterile powder for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Immune System Activator
Description: sterile powder for injection
Study: NCT05351320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WX-0593 Tablets
Description: WX-0593 60 mg, tablets, orally, once daily for 7 days, followed by WX-0593 180 mg, tablets, orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: Platinum-based chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiation Therapy（TRT）
Description: Five days a week to accept chest radiotherapy, once per day, every time 1.8-2.0 Gy, total dose 54-66 Gy
Study: NCT04821297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion and Education
Description: Receive messages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in an interview
Study: NCT06105853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test
Description: Test to induce high levels of acute social stress, including actors, representing the judging panel, and a faked exam situation (15 minutes duration).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Barlab Cue-Exposure
Description: Participants are exposed to a bar situation with their individual favorite alcohol presented. They handle their favorite alcoholic drink and water (9 minutes duration).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging
Description: Participants undergo a fMRI screening including three different behavioral tasks assessing alcohol cue reactivity, response inhibition, and emotion processing
Study: NCT05096520

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency
Description: the radiofrequency needle will be advanced percutaneously towards the intermedius genicular nerve on the periosteum of the distal femoral shaft region until bone contact is achieved. In addition to imaging the nerve with ultrasound, sensory stimulation at 50 Hz frequency will be applied with a threshold value less than 0.6 V in order to determine its position more accurately. In order to prevent the inactivation of the motor nerves, the relevant nerve will be tested for the absence of fasciculation in the region of the lower extremity compatible with the application with the stimulation with a frequency of 2.0 V and 2 Hz. Before the activation of the Baylis brand radiofrequency generator, an injection of 1 ml of 2% lidocaine will be made, then the radiofrequency electrode will be added to the needle and the temperature level at the tip of the electrode will be increased to 80 degrees for 2 minutes, the procedure will be performed for each genicular nerve.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: The intermedius genicular nerve will be found under US guidance and the genicular nerve will be blocked by injecting 1 ml of 2% lidocaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% lidocaine
Description: 2% lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% lidocaine
Description: 2% lidocaine
Study: NCT06003322

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non - Incised Papilla surgical approach NIPSA for intrabony defect
Description: As described by Rodríguez and Caffesse in 2018, a single incision apical to the defect ,on the buccal aspect, only one apical horizontal or oblique incision will be made in the alveolar mucosa, as far removed as possible from the interdental papillae and marginal keratinized tis- sues.~Following flap reflection, the bony defect will be examined carefully. Root planing is performed,. Flap closure will be performed by horizontal mattress sutures, placed 3 mm away from the borders, will be used as the first line of closure, promoting connective tissue contact between both edges of the incision, and single interrupted sutures will then be placed as a second line of closure. Using 5/0 polypropylene monofilament suture, Assut, Swiss

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single-flap approach SFA
Description: As described by Trombelli et al 2010, A horizontal, butt-joint incision will be performed at the interdental papilla 1-2 mm coronal to the bone crest (as detected through pre-operative bone sounding).~-A buccal mucoperiosteal envelope flap will be elevated by using a microsurgical periosteal elevator, leaving the residual portion of the interdental supracrestal soft tissues undetached.Flap closure will be performed by a horizontal internal mattress suture,will be performed at the base of the papilla, and a second internal mattress suture (vertical or horizontal) was performed between the most coronal portion of the flap and the most coronal portion of the palatal/lingual papilla. Using a resorbable suture
Study: NCT06382402

Intervention type: RADIATION
Intervention: CCTA scan
Description: • CCTA will be performed per the standard clinical protocol using a Cannon Aquilion ONE scanner with 16 cm z-axis coverage at 0.5 mm resolution, low contrast, and reduced radiation dose requirements.
Study: NCT05591157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CSF-3 watch, designed to monitor a user's heart rate based on ECG (electrocardiogram) and PPG (Photoplethysmograph) readings
Description: The subjects will be connected to an ECG Holter, and an investigational Device will be placed simultaneously on the subject's wrist. All subjects in this phase will be asked to participate in a single continuous data recording measurement for seven (7) minutes
Study: NCT05055726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzydamine Hydrochloride 0.15% w/v oromucosal solution
Description: Benzydamine Hydrochloride 0.15% w/v oromucosal solution (mouthwash), Angelini Pharma S.p.A.
Study: NCT06470490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducational
Description: educational program
Study: NCT04662060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acebilustat
Description: 100 mg capsule administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match acebilustat administered orally once daily
Study: NCT05722717

Intervention type: GENETIC
Intervention: Saliva collection at home
Description: Children (with help of their parents) collect their saliva with a saliva collection kit which they send to our research center.
Study: NCT05630534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline is a tetracycline antibiotic routinely used in clinical practice for the treatment of bacterial infection and acne.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: starch
Description: Use starch capsules as placebo
Study: NCT05722717

Intervention type: GENETIC
Intervention: Saliva collection at home
Description: Children (with help of their parents) collect their saliva with a saliva collection kit which they send to our research center.

Intervention type: GENETIC
Intervention: Saliva collection at home
Description: Children (with help of their parents) collect their saliva with a saliva collection kit which they send to our research center.
Study: NCT04784234

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GlaucoCetin
Description: GlaucoCetin, a medical food in capsule form, is FDA regulated and includes ingredients that have been shown to support and protect mitochondrial function of retinal ganglion cells. GlaucoCetin consists of a mixture of Curcumin, N-Acetyl Cysteine, Ginkgo Biloba Extract, Alpha-lipoic Acid, Citicoline, Grape Seed Extract, Green Tea Extract, and Coenzyme Q10. Additional ingredients include L-Taurine, Niacinamide, Biotin, Natural Astaxanthin, Fisetin, Quercetin, Luteolin, Proprietary Dragonberry Flavor Complex, Monk Fruit, Bitter Blocker Natural Flavor, Citric Acid, Silica Dioxide, Fibersol-2, L-Leucine. Many of these are known anti-inflammatory and antioxidant ingredients. A 6 month supply of capsules, made for this study, will be provided at randomization with the following instructions: Take 6 capsules by mouth once daily with food.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GlaucoCetin
Description: GlaucoCetin, a medical food in capsule form, is FDA regulated and includes ingredients that have been shown to support and protect mitochondrial function of retinal ganglion cells. GlaucoCetin consists of a mixture of Curcumin, N-Acetyl Cysteine, Ginkgo Biloba Extract, Alpha-lipoic Acid, Citicoline, Grape Seed Extract, Green Tea Extract, and Coenzyme Q10. Additional ingredients include L-Taurine, Niacinamide, Biotin, Natural Astaxanthin, Fisetin, Quercetin, Luteolin, Proprietary Dragonberry Flavor Complex, Monk Fruit, Bitter Blocker Natural Flavor, Citric Acid, Silica Dioxide, Fibersol-2, L-Leucine. Many of these are known anti-inflammatory and antioxidant ingredients. A 6 month supply of capsules, made for this study, will be provided at randomization with the following instructions: Take 6 capsules by mouth once daily with food.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is an identical capsule to the GlaucoCetin, made for this study, with no nutritional value. A 6 month supply of capsules will be provided at randomization with the following instructions: Take 6 capsules by mouth once daily with food.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is an identical capsule to the GlaucoCetin, made for this study, with no nutritional value. A 6 month supply of capsules will be provided at randomization with the following instructions: Take 6 capsules by mouth once daily with food.
Study: NCT06320210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent program
Description: The intervention is a multi-component program that includes in-depth training for current school teachers/staff who are critical in asthma care, restructured processes to identify students with asthma, technological adaptations to support integrated systems for asthma care and absenteeism, strategies to enhance communication about asthma within school and between school and home, protocols for routine care (e.g., participation in gym/recess) and emergencies, and education for all students about asthma.
Study: NCT06166017

Intervention type: OTHER
Intervention: Exposure to minimal amount of lingual keratinized tissue width
Description: measurement of clinical parameters
Study: NCT05914350

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound guided Ozone, platelet-rich plasma or steroid injection in the treatment of sacroiliitis
Description: ultrasound guided Ozone, platelet-rich plasma or steroid injection in the treatment of sacroiliitis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound guided Ozone, platelet-rich plasma or steroid injection in the treatment of sacroiliitis
Description: ultrasound guided Ozone, platelet-rich plasma or steroid injection in the treatment of sacroiliitis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound guided Ozone, platelet-rich plasma or steroid injection in the treatment of sacroiliitis
Description: ultrasound guided Ozone, platelet-rich plasma or steroid injection in the treatment of sacroiliitis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone acetate and lidocaine
Description: 40 mg methylprednisolone acetate and 1 mL lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRP and lidocaine
Description: 3 mL PRP and 1 mL lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medical ozone
Description: 10 ml of medical ozone
Study: NCT06410664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 72-hour HME exchange interval group
Description: All patients in the experimental arm will receive the usual best medical and nursing care with respect to VAP prevention. A dual-limb ventilator circuit with a closed suction system will be used. Bronchodilation or inhalational antibiotics, when ordered, will be delivered by a meshed nebuliser, a part of the ventilatory support circuit and will not be removed between treatments. A closed-circuit suction device will be used, and the frequency of suctioning will be monitored, including the sputum consistency and blood on suctioning. HME filter resistance by estimating the pressure drop over HME using the ventilatory circuit's auxiliary force (Paux) and flow. Temperature and humidity in the ventilator circuit will be measured. HME filters will be exchanged every 72 hours. At the exchange point, both outlets of the HME filter will be swabbed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 24-hour HME exchange interval group
Description: All patients in the control arm will receive the usual best medical and nursing care with respect to VAP prevention. A dual-limb ventilator circuit with a closed suction system will be used. Bronchodilation or inhalational antibiotics, when ordered, will be delivered by a meshed nebuliser, a part of the ventilatory support circuit and will not be removed between treatments. A closed-circuit suction device will be used, and the frequency of suctioning will be monitored, including the sputum consistency and blood on suctioning. HME filter resistance by estimating the pressure drop over HME using the ventilatory circuit's auxiliary force (Paux) and flow. Temperature and humidity in the ventilator circuit will be measured. HME filters will be exchanged every 24 hours. At the exchange point, both outlets of the HME filter will be swabbed.